Pfizer Offers €374M for German mRNA Flu Vaccine
BioNTech, based in Mainz, Germany, has entered into a partnership with Pfizer worth up to $425M (€374M) to develop an mRNA-based flu vaccine.
Pfizer Offers €374M for German mRNA Flu Vaccine
Source: Virology News